Steve Davies

Steve Davies obtained his Bachelor of Arts degree in 1973 from New College, Oxford, and his Doctor of Philosophy in 1975 under the supervision of Gordon H. Whitham. 

After his PhD, Davies subsequently held an ICI Postdoctoral Fellowship working with Malcolm Green and a NATO Fellowship working with Derek Barton before joining the Centre national de la recherche scientifique (CNRS) at Gif-sur-Yvette as Attaché de Recherche working with Hugh Felkin.

In 1980 he returned to Oxford to take up a University Lectureship in Chemistry. Whilst remaining an active academic, in 1991 he founded Oxford Asymmetry Ltd (an asymmetric synthesis company) as sole investor.[5] He also founded Oxford Diversity Ltd (a combinatorial chemistry company). These two companies were combined to form Oxford Asymmetry International Plc in 1999 which was sold to Evotec in 2000, valued at £316m. In 2003 he founded VASTox (Value Added Screening Technology Oxford) a zebrafish screening company. It floated on AIM in 2004 and has since acquired Dainolabs (zebrafish) and Dextra (a carbohydrate chemistry company) as well as the assets of MNL Pharma.[6] VASTox then changed its name to Summit. In 2009 the zebrafish screening operation was acquired by Evotec for £0.5 Million. In 1996, he became Professor of Chemistry and in 2006, Waynflete Professor of Chemistry.

Davies is founder and editor-in-chief for Tetrahedron: Asymmetry.

Davies along with Malcolm Green and Michael Mingos have compiled a set of rules that summarize where nucleophilic additions will occur on pi ligands.